Physician profile
Thomas Green
NPI 1932106093
$1,040.35
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.18 · 2020: $124 · 2021: $340 · 2022: $223 · 2023: $107 · 2024: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $201.55 | 2021-2024 | |
| Novo Nordisk INC | $146.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $102.19 | 2019-2021 | |
| Daiichi Sankyo INC. | $64.84 | 2022-2024 | Injectafer |
| Pfizer INC. | $56.29 | 2019-2022 | |
| Biogen, INC. | $46.33 | 2021 | |
| Abbvie INC. | $45.88 | 2021 | |
| Amgen INC. | $38.84 | 2024 | Tavneos |
| Eisai INC. | $36.33 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $34.92 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $25.61 | 2024 | Acthar |
| Calliditas Therapeutics US INC. | $25.52 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.41 | 2024 | Xifaxan |
| Lundbeck LLC | $20.30 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $19.50 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.61 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.00 | 2023 | Rexulti |
| Beigene USA, INC. | $16.91 | 2022 | |
| Acadia Pharmaceuticals INC | $16.69 | 2020 | |
| Opko Pharmaceuticals, LLC | $15.84 | 2022 | |
| Corium, LLC | $15.40 | 2023 | Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $15.25 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.34 | 2024 | Nuzyra |
| Almatica Pharma LLC | $12.75 | 2021 | |
| Scilex Pharmaceuticals INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.